Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05783323 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 14, 2025 (before its estimated October 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 5 sites
    • Eligibility criteria expanded, about 4 words
    v16
  2. Study sites: 3 to 5v15
  3. Site contacts updated at 1 of 3 sitesv14
  4. Study sites: 2 to 3v13
  5. Site contacts updated at 1 of 2 sitesv12
Show 10 earlier versionsHide 10 earlier versions
  1. Study sites: 1 to 2v11
  2. Primary completion date: Oct 1, 2024 to Oct 1, 2026v10
  3. Site contact updatedv9
  4. Re-verified, no change to tracked fieldsv8
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 2024 to Feb 14, 2024
    v7
  6. Start date: Nov 2023 to Feb 2024v6
  7. Start date: Aug 2023 to Nov 2023v5
  8. Start date: Jul 2023 to Aug 2023v4
  9. Start date: May 15, 2023 to Jul 2023v3
  10. Lead sponsor: Theodore Laetsch to Children's Hospital of Philadelphia
    • Start date: Apr 1, 2023 to May 15, 2023
    • Primary completion date: Sep 1, 2024 to Oct 1, 2024
    • Study completion date: Sep 1, 2027 to Oct 1, 2027
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Trial Details
NCT Number NCT05783323
Lead Sponsor Children's Hospital of Philadelphia
Collaborators: Bayer
Conditions
(from sponsor)		 Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Related terms Neoplasms, Thyroid Neoplasms
Enrollment 13 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov